The Efficacy and Safety of DA-3030 (Recombinant Human Granulocyte Colony-Stimulating Factor) in Neutropenia after the Remission Induction Chemotherapy in Patients with Acute Myelogenous Leukemia / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 66-68, 2003.
Artículo
en Inglés
| WPRIM
| ID: wpr-78029
ABSTRACT
PURPOSE:
This study was conducted to determine the efficacy and safety of DA-3030 (a recombinant methionyl human granulocyte colony-stimulating factor, rhG-CSF), after remission induction chemotherapy, in patients with acute myelogenous leukemia (AML). MATERIALS ANDMETHODS:
After the remission induction chemotherapy, with idarubicin (12 mg/m2/day for 3 days) and cytarabine (200 mg/m2/day for 7 days), 26 patients with newly diagnosed AML were assigned to receive DA-3030 (200mug/m2/day), starting 24 hours after the completion of the remission induction chemotherapy, until their neutrophil count recovered to greater than 1, 000/muL for 3 consecutive days.RESULTS:
The median time from the initiation of the chemotherapy to the neutrophil recovery of 1, 000/muL was 21 days (range, 12~41). Treatment with DA-3030 was not associated with significant adverse side effects. The most frequently reported side effects were musculo-skeletal pain (13%) and headache (13%).CONCLUSION:
The DA-3030 is a safe rhG-CSF for the treatment of neutropenia after remission induction chemotherapy in patients with AML.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Inducción de Remisión
/
Idarrubicina
/
Leucemia Mieloide Aguda
/
Factor Estimulante de Colonias de Granulocitos
/
Citarabina
/
Quimioterapia
/
Granulocitos
/
Cefalea
/
Neutropenia
/
Neutrófilos
Límite:
Humanos
Idioma:
Inglés
Revista:
Cancer Research and Treatment
Año:
2003
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS